A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Real-World Data For Pertuzumab and T-DM1 Demonstrates Inferior Outcomes Versus HER2+ Breast Cancer Clinical Trialson August 1, 2021 at 11:00 am
Compared with pivotal phase 3 trials, the use of pertuzumab in the frontline and T-DM1 in the second-line setting for HER2-positive metastatic breast cancer may lead to shorter survival outcomes.
- Study: Cancer treatment outcomes can be accessed by studying DNA tagson August 1, 2021 at 10:45 am
Georgetown Lombardi Comprehensive Cancer Center researchers found that studying tags, or modifications to cell-free DNA (cfDNA), may lead to a better understanding of how to assess, and possibly ...
- Dallas Cowboys make it Christmas in July for teenager who's in OKC for cancer treatmenton August 1, 2021 at 10:20 am
It was like Christmas in July. A teen boy who has cancer and is being treated in Oklahoma City received a surprise from the Dallas Cowboys on Wednesday. Sign up for our Newsletters It’s all thanks to ...
- These Celebrities Have the Most Inspiring Things to Say About Battling Canceron August 1, 2021 at 9:45 am
"The cancer served a real purpose, making me a little bit more conscious of time," said Gloria Steinem. Cancer is a disease that affects most of us at some point in our lives—whether it be our own ...
- Black scientist fights to fund her potential cancer laser treatment: Bias in health fundingon August 1, 2021 at 9:33 am
For the last five years, Dr. Hadiyah-Nicole Green, a physicist and cancer researcher, has fought to fund her cancer ...
- Rabinowits Discusses Treatment Options in Medullary Thyroid Canceron August 1, 2021 at 7:00 am
During a Targeted Oncology Case-Based Roundtable event, Guilherme Rabinowits, MD, discussed the case of a 58-year-old patient with medullary thyroid cancer.
- Fla. woman chooses cancer treatment over job, homeon July 30, 2021 at 8:54 am
At 32 years old, Liliana Herrera had to quit her job, live in a warehouse and sleep on a chair – just to get the life-saving chemotherapy she needed after being diagnosed with breast cancer for the ...
- Theranostics: Clinic transforms cancer treatment by combining diagnosis and therapyon July 29, 2021 at 12:35 pm
Conventional treatments for cancer, such as chemotherapy, external beam radiation and surgery, don't always work, but hope is on the horizon for some patients with certain cancers.
- BERG Reveals New Study That Will Seek to Enhance Diagnosis and Treatment of Prostate Canceron July 29, 2021 at 6:52 am
BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments and diagnostics, today announced the publication of ...
via Bing News